Country: United States
Language: English
Source: NLM (National Library of Medicine)
zoledronic acid (UNII: 6XC1PAD3KF) (zoledronic acid anhydrous - UNII:70HZ18PH24)
Sagent Pharmaceuticals
INTRAVENOUS
PRESCRIPTION DRUG
Zoledronic Acid Injection is indicated for the treatment of hypercalcemia of malignancy defined as an albumin-corrected calcium (cCa) of greater than or equal to 12 mg/dL [3 mmol/L] using the formula: cCa in mg/dL = Ca in mg/dL + 0.8 (4 g/dL – patient albumin [1g/dL]). Zoledronic Acid Injection is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. Limitations of Use The safety and efficacy of Zoledronic Acid Injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions have not been established. Hypersensitivity reactions including cases of urticaria and angioedema, and cases of anaphylactic reaction/shock have been reported [see Adverse Reactions (6.2)] . Risk Summary Based on findings from animal studies and its mechanism of action,
Zoledronic Acid Injection is supplied as follows: Storage Conditions Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature.] Discard unused portion. Sterile, Nonpyrogenic, Preservative-free, DEHP-free, PVC-free. The container and container closure are not made with natural rubber latex.
New Drug Application
ZOLEDRONIC ACID- ZOLEDRONIC ACID INJECTION, SOLUTION SAGENT PHARMACEUTICALS ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE ZOLEDRONIC ACID INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ZOLEDRONIC ACID INJECTION. ZOLEDRONIC ACID INJECTION, FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 2001 RECENT MAJOR CHANGES Warnings and Precautions, Embryo-Fetal Toxicity (5.10) 10/2020 INDICATIONS AND USAGE Zoledronic Acid Injection is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy. (1.1) Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. (1.2) Limitations of Use: The safety and efficacy of Zoledronic Acid Injection has not been established for use in hyperparathyroidism or non-tumor-related hypercalcemia. DOSAGE AND ADMINISTRATION Hypercalcemia of malignancy (2.1) 4 mg as a single-dose intravenous infusion over no less than 15 minutes. (2.1) 4 mg as retreatment after a minimum of 7 days. (2.1) Multiple myeloma and bone metastasis from solid tumors. (2.2) 4 mg as a single-dose intravenous infusion over no less than 15 minutes every 3 to 4 weeks for patients with creatinine clearance of greater than 60 mL/min. (2.2) This premixed ready-to-use bag is intended only for patients with normal renal function (creatinine clearance greater than 60 mL/min.) (2.2) Coadminister oral calcium supplements of 500 mg and a multiple vitamin containing 400 international units of vitamin D daily. (2.2) Administer through a separate infusion line and do not allow to come in contact with any calcium or divalent cation-containing solutions. (2.3) DOSAGE FORMS AND STRENGTHS Zoledronic Acid Injection: 4 mg in a 100 mL (0.04 mg per mL) single-dose bag (3) CONTRAINDICATIONS Hypersensitivity to any component of Zoledronic Acid Injection (4) WARNINGS AND Read the complete document